EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Micro-randomization trial design under operational constraints

Bryan Bunning, Victor Ritter, Franziska K Bishop, Jonathan H Chen, Victoria Ding, Ramesh Johari, Blake Shaw, David Scheinker, Priya Prahalad, Isha Thapa, David M Maahs, Manisha Desai

Contemporary Clinical Trials · 2026-07 · 166 · 108351

DOI: 10.1016/j.cct.2026.108351 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2026-07. Verfasst von Bryan Bunning und 11 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative Sciences Unit, Section of Biostatistics, Department of Medicine, Stanford University, Stanford, CA, USA; Computational Medicine, Departm…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Research Design, Hypoglycemic Agents, Randomized Controlled Trials as Topic. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Center for Advancing Translational Sciences, National Library of Medicine, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Micro-randomization is a common method used to design and tailor AI-driven digital health interventions. However, applying it in real-world clinical settings can be challenging particularly when there are operational or resource constraints. We propose a novel design that integrates micro-randomization with treatment allocation policies to address such constraints, inspired by a pediatric type 1 diabetes (T1D) program. METHODS: We evaluated the design's properties through an extensive simulation study and developed a simulation-based power calculator, MRThreshold, to support such trial designs. RESULTS: Operational constraints that led to imbalance in treatment assignment affected efficiency. However, increasing resources had less impact relative to increases in study length (i.e., opportunities for micro-randomization). We observed a > 50% increase in power when lengthening a 16-week study to a 40-week study. Using our power calculator, we demonstrated that a 40-week study with 100 patients provides 84.0% power to detect a 2% change in time spent in glucose control, providing design considerations for our study. CONCLUSIONS: Careful consideration of study length, sample size, and operational capacity is essential for thoughtful design. Our novel design and tool balance micro-randomization and treatment allocation under operational constraints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Research DesignHypoglycemic AgentsRandomized Controlled Trials as TopicHumansComputer SimulationSample SizeInsulinDigital HealthBlood Glucose

Stichwörter der Autor:innen

CGMDiabetesMicro-randomizationMonitoringRemoteWearables

Substanzen

Hypoglycemic AgentsInsulinBlood Glucose

Autor:innen und Institutionen

  • Quantitative Sciences Unit, Section of Biostatistics, Department of Medicine, Stanford University, Stanford, CA, USA; Computational Medicine, Department of Medicine, Stanford University, Stanford, CA, USA.
  • Quantitative Sciences Unit, Section of Biostatistics, Department of Medicine, Stanford University, Stanford, CA, USA.
  • Division of Pediatric Endocrinology, Department of Pediatrics, Stanford University, Stanford, CA, USA; Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA.
  • Computational Medicine, Department of Medicine, Stanford University, Stanford, CA, USA; Clinical Excellence Research Center, Stanford University, Stanford, CA, USA.
  • Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA; Department of Management Science and Engineering, Stanford University, Stanford, CA, USA.
  • Division of Pediatric Endocrinology, Department of Pediatrics, Stanford University, Stanford, CA, USA; Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA; Department of Management Science and Engi…

Förderung

  • National Center for Advancing Translational Sciences
  • National Library of Medicine
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Cancer Institute Division of Cancer Prevention

Zitieren

APA

Bunning, B., Ritter, V., Bishop, F. K., Chen, J. H., Ding, V., Johari, R., Shaw, B., Scheinker, D., Prahalad, P., Thapa, I., Maahs, D. M., & Desai, M. (2026). Micro-randomization trial design under operational constraints. Contemporary Clinical Trials, 166, 108351. https://doi.org/10.1016/j.cct.2026.108351

Vancouver

Bunning B, Ritter V, Bishop FK, Chen JH, Ding V, Johari R, et al. Micro-randomization trial design under operational constraints. Contemporary Clinical Trials. 2026;166:108351. doi:10.1016/j.cct.2026.108351

BibTeX
@article{Bunning2026,
  author = {Bunning, Bryan and Ritter, Victor and Bishop, Franziska K and Chen, Jonathan H and Ding, Victoria and Johari, Ramesh and Shaw, Blake and Scheinker, David and Prahalad, Priya and Thapa, Isha and Maahs, David M and Desai, Manisha},
  title = {Micro-randomization trial design under operational constraints},
  journal = {Contemporary Clinical Trials},
  year = {2026},
  volume = {166},
  pages = {108351},
  doi = {10.1016/j.cct.2026.108351}
}
Kostenlos starten →